A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Más betegség

• Any disorder, unwillingness, or inability which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.
• Presence or history of any clinically relevant respiratory, metabolic, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions(except conditions associated with renal impairment or ESRD).

Laborértékek

• Use of drugs known to affect creatinine clearance including cephalosporin and aminoglycoside, antibiotics, flucytosine, cisplatin, cimetidine, trimethoprim, cibenzoline, and nitrofurantoin within 14 days or 5 half-lives, whichever is greater, before dosing the investigational medicinal product (IMP).

• Male or female, aged 18-80 years (both inclusive) at the time of signing the informed consent
• Body mass index (BMI) between 20.0 and 39.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening.
• Meeting the pre-defined eGFR values based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation (2021) adjusted for the estimated individual body surface area (BSA);
  • Normal renal function - greater than or equal to 90 mL/min
  • Mild renal impairment - 60 - 89 (mL/min)
  • Moderate renal impairment - 30 - 59 (mL/min)
  • Severe renal impairment - less than 30 (mL/min) not requiring dialysis
  • End-stage renal disease (ESRD) - Requiring dialysis treatment
• For ESRD: Participants requiring dialysis treatment should be on current treatment with haemodialysis.